Skip to content
Ilumya, Ilumetri(tildrakizumab)
Ilumetri, Ilumya (tildrakizumab) is an antibody pharmaceutical. Tildrakizumab was first approved as Ilumya on 2018-03-20. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis. It is known to target interleukin-23 subunit alpha.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Ilumya
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Tildrakizumab
Tradename
Proper name
Company
Number
Date
Products
Ilumyatildrakizumab-asmnSun Pharma Global FZEN-761067 RX2018-03-20
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
ilumyaBiologic Licensing Application2021-02-11
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
psoriasisEFO_0000676D011565L40
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AC: Interleukin inhibitors
— L04AC17: Tildrakizumab
HCPCS
Code
Description
J3245
Injection, tildrakizumab, 1 mg
Clinical
Clinical Trials
24 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PsoriasisD011565EFO_0000676L40—2610219
Inborn genetic diseasesD030342EFO_0000508———1—1
InflammationD007249———1—1
AgingD000375GO_0007568R41.81———1—1
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Castration-resistant prostatic neoplasmsD06412911———1
Hematologic neoplasmsD019337—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bullous pemphigoidD010391EFO_0007187L121————1
VitiligoD014820EFO_0004208L801————1
Skin diseasesD012871L00-L991————1
Skin and connective tissue diseasesD0174371————1
Pigmentation disordersD010859L81.91————1
HypopigmentationD017496HP_00010101————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pregnancy rateD018873————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTILDRAKIZUMAB
INNtildrakizumab
Description
Tildrakizumab (humanized mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID1326244-10-3
RxCUI2053436
ChEMBL IDCHEMBL2108681
ChEBI ID—
PubChem CID—
DrugBankDB14004
UNII IDDEW6X41BEK (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
IL23A
IL23A
Organism
Homo sapiens
Gene name
IL23A
Gene synonyms
SGRF
NCBI Gene ID
51561
Protein name
interleukin-23 subunit alpha
Protein synonyms
IL-23 subunit alpha, IL-23-A, IL-23p19, interleukin 23 p19 subunit, interleukin 23, alpha subunit p19, Interleukin-23 subunit p19, interleukin-six, G-CSF related factor, JKA3 induced upon T-cell activation
Uniprot ID
Q9NPF7
Mouse ortholog
Il23a (83430)
interleukin-23 subunit alpha (Q9EQ14)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 905 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3,287 adverse events reported
View more details